Can mirtazapine be prescribed to a patient with adrenal insufficiency who is receiving stable glucocorticoid replacement therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mirtazapine Can Be Used in Adrenal Insufficiency with Stable Glucocorticoid Replacement

Yes, mirtazapine can be prescribed to patients with adrenal insufficiency who are receiving stable glucocorticoid replacement therapy, but requires careful monitoring for hyponatremia and awareness of potential drug interactions that could precipitate adrenal crisis.

Key Considerations

No Direct Contraindication

Neither the FDA labeling for mirtazapine 1 nor the major adrenal insufficiency guidelines 2, 3 identify adrenal insufficiency as a contraindication to mirtazapine use. The primary concern is not the diagnosis itself, but rather the management of specific risks that could destabilize a patient with AI.

Critical Risk: Hyponatremia

The most important consideration is mirtazapine's risk of causing hyponatremia through SIADH 1. This is particularly dangerous in adrenal insufficiency because:

  • Hyponatremia is already a hallmark feature of adrenal insufficiency, especially primary AI 2
  • Mirtazapine can cause severe hyponatremia (serum sodium <110 mmol/L has been reported) 1
  • Worsening hyponatremia could mask inadequate glucocorticoid replacement or precipitate adrenal crisis

Monitor serum sodium closely when initiating mirtazapine in patients with AI, particularly within the first few weeks of treatment. Check baseline sodium and recheck at 2-4 weeks, then periodically thereafter.

Glucocorticoid Replacement Must Be Optimized First

Before prescribing mirtazapine, ensure the patient's glucocorticoid replacement is stable and adequate 2, 3:

  • Hydrocortisone 15-25 mg/day (or cortisone acetate 20-35 mg/day) in divided doses 2
  • For primary AI: Fludrocortisone 50-100 mcg/day with adequate salt intake 2
  • Monitor for signs of under-replacement: fatigue, postural hypotension, salt craving, hyponatremia 2
  • Monitor for signs of over-replacement: weight gain, hypertension, hyperglycemia 2

Additional Monitoring Considerations

Somnolence and functional impairment: Mirtazapine causes somnolence in 54% of patients 1. In patients with AI who already experience fatigue as a core symptom, this could complicate assessment of glucocorticoid replacement adequacy. Distinguish between:

  • Medication-induced sedation (improves with dose adjustment or time)
  • Inadequate glucocorticoid replacement (requires dose increase)

Weight gain: Mirtazapine causes significant weight gain (≥7% body weight in 7.5% of patients) 1. This could be mistaken for glucocorticoid excess, potentially leading to inappropriate dose reduction of replacement therapy.

Drug Interaction Alert

While not specifically documented, be aware that mirtazapine's sedative effects combined with the stress of illness could theoretically mask early signs of adrenal crisis. Educate patients that if they develop:

  • Severe nausea/vomiting
  • Severe weakness beyond usual mirtazapine sedation
  • Confusion or altered mental status
  • Fever or acute illness

They should immediately increase their glucocorticoid dose (stress dosing) and seek medical attention, rather than attributing symptoms solely to mirtazapine side effects.

Practical Algorithm for Prescribing

  1. Confirm stable AI management: Patient on appropriate glucocorticoid ± mineralocorticoid replacement for ≥3 months with good adherence
  2. Check baseline sodium: Must be normal or near-normal before starting mirtazapine
  3. Start mirtazapine at standard dosing: 15 mg at bedtime initially 1
  4. Recheck sodium at 2 weeks and 4 weeks: Discontinue if sodium drops significantly
  5. Reassess fatigue/energy: Ensure worsening fatigue is not mistaken for inadequate AI treatment
  6. Provide stress dosing education: Reinforce sick-day rules and when to increase glucocorticoids

Common Pitfalls to Avoid

  • Do not attribute all fatigue to mirtazapine: Always consider inadequate glucocorticoid replacement
  • Do not reduce glucocorticoids for weight gain: Unless clear Cushingoid features develop; mirtazapine itself causes weight gain
  • Do not ignore hyponatremia: This is a medical emergency in AI patients and requires immediate evaluation
  • Do not forget stress dosing education: Patients must understand when to increase glucocorticoids during illness, regardless of psychiatric medication use

The combination is safe when glucocorticoid replacement is optimized and sodium is monitored appropriately.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.